Medical

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

Latest real-world data published, providing real evidence of the effectiveness of Azulfidine in patients with COVID-19

The pursuit of eternal beauty is the dream of every woman. For thousands of years, many people have made unremitting efforts to achieve the goal of beauty, so many stories about beauty have emerged.

Communication between doctors and patients is an art, and communication between patients and doctors also requires skills. This is not only a need for interpersonal communication, but also a need for the vital interests of patients.

Recent findings show that the use of cutting-edge immune checkpoint inhibitor therapy (referred to as immunotherapy in this article) has increased rapidly over the past decade in the population of patients with advanced non-small cell lung cancer (NSCLC), but the survival benefit is more pronounced in younger people than in older people, who have limited survival benefit with this therapy.

It is estimated that ninety percent of deaths from breast cancer are caused by complications from metastasis, so how to effectively stop breast cancer metastasis has long been a hot topic in cancer research.

Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.

The US FDA has approved Elacestrant, the first oral selective estrogen receptor degrader (SERD), for the treatment of patients with advanced or metastatic breast cancer who are estrogen receptor positive, HER2 negative and have an ESR1 mutation. Results of the trial showed that patients treated with Elacestrant had a 45% reduction in the risk of disease progression or death.

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!

In our intestines, there are a wide variety of intestinal microorganisms, which are called intestinal microflora. Many studies have proved that they play an extremely important role in maintaining normal digestion and absorption, regulating immunity and preventing pathogen invasion.